NasdaqGM:WVEPharmaceuticals
Failed Obesity Trial And Investor Exit Might Change The Case For Investing In Wave Life Sciences (WVE)
In early June 2026, Wave Life Sciences reported that its obesity candidate WVE-007 failed to show meaningful clinical improvement, and institutional investor Exome Asset Management exited its entire position as the company presented at major healthcare conferences hosted by Jefferies and Goldman Sachs.
This combination of disappointing trial data and the swift withdrawal of a specialist investor has sharpened attention on how Wave will allocate capital and prioritize its remaining RNA-based...